Yue Ma

机构：Fujian Medical University, Shanxi Medical University, The Affiliated Yongchuan Hospital of Chongqing Medical University, Taiyuan Central Hospital, Chongqing Medical University · ORCID：0000-0002-0170-9236

发表论文 42 篇 · 总被引 387 次 · h-index 11

代表论文

• Inhibition of HDAC2 sensitises antitumour therapy by promoting NLRP3/GSDMD‐mediated pyroptosis in colorectal cancer (2024 · Clinical and Translational Medicine · 被引 51)
• Efficacy and safety of tislelizumab plus lenvatinib as first-line treatment in patients with unresectable hepatocellular carcinoma: a multicenter, single-arm, phase 2 trial (2024 · BMC Medicine · 被引 33)
• Prognostic Effect of the Controlling Nutritional Status Score in Patients With Esophageal Cancer Treated With Immune Checkpoint Inhibitor (2022 · Journal of Immunotherapy · 被引 27)
• Surufatinib plus toripalimab in patients with advanced neuroendocrine tumours and neuroendocrine carcinomas: An open-label, single-arm, multi-cohort phase II trial (2024 · European Journal of Cancer · 被引 21)
• A phase II study combining KN046 (an anti-PD-L1/CTLA-4 bispecific antibody) and lenvatinib in the treatment for advanced unresectable or metastatic hepatocellular carcinoma (HCC): Updated efficacy and safety results. (2022 · Journal of Clinical Oncology · 被引 16)
• Dynamic radiological features predict pathological response after neoadjuvant immunochemotherapy in esophageal squamous cell carcinoma (2024 · Journal of Translational Medicine · 被引 10)